Leishmaniasis

From Wikipedia
Jump to: navigation, hwehwɛ
Leishmaniasis
Nsεm a wͻahyehyε ne baabi a wonya nsεm afoforo
ICD/CIM-10 B55 B55
ICD/CIM-9 085 085
DiseasesDB 3266
MedlinePlus 001386

Leishmaniasis, a wͻsan kyerεw no leishmaniosisyare a mmoawa bi a wͻte afoforo mu a wͻwͻ abusuakuw leishmania mu a wonya denam dͻte ntuboaso[1] Yare no nam kwan abiεsa so da ne ho adi:honam yare, εhorow ne honam ani, anaa nipaduam leishmaniasis[1] Honam ani de no da adi denam honam kuru ahorow so, bere a εhorow ne honam de da adi denam kuru wͻ honam ani, obi anum, ne ne hwenem, na nipaduam de da adi denam honam kuru ne afei atiridii, mogya a akͻ fam ne berεbo a ayε kεse so.[1][2]

"Leishmania" ahorow bεboro aduonu na wͻde yare yi ma nipa.[1] Nea εta de ba binom yε ohia, aduan pa a wonnya, kwae a wͻsεe no, ne kurow kεse mu tena.[1] Yare abiεsa no nyinaa yε nea wobetumi de afidie ahu.[1] Bio nso, wotumi hu nipaduam de no denam mogya mu a wͻhwehwε so.[2]

Wobetumi asiw Leishmaniasis kwan denam ntama a wͻde aduru ahyε no a wͻdam.[1] Akwan afoforo yε nnuru a wͻde kum ntummoa no ne nipa a woanya a wͻsa wͻn yare ntεm so.[1] Ayaresa a wͻde ma gyina baabi a wonyaa yare no, "Leishmania" ko, ne yare ko.[1] Nnuru a wͻde sa nipaduam yare no bi ne liposomal amphotericin B[3] Nnuru yi nso - nnuru a n'hoͻden bͻ ho anum ne paromomycin,[3]ne miltefosine.[4]Ɛdefa honam ani de ho no, paromomycin, fluconazole, anaa pentamidine betumi ayε adwuma.[5]

Mprempren, nipa bεyε ͻpepem dumien na wͻanya yare yi[6]wͻ aman aduokrͻn awotwe so.[2] Bεyε nipa ͻpepem abien na wonya yare yi foforo[2] ne bεyε aduonu kosi aduonum na wͻhwere wͻn nkwa afe biara.[1][7] Nipa bεyε ͻpepem ahanu wͻ Asia, Afrika, Amεrika Anaafo ne Mfinimfini ne Europa Anaafo na wͻtete mmeae a yare yi abu so.[2][8] Wiase Akwanhosan Ahyehyεde(WHO) anya nteso wͻ nnuru a wͻde sa yare no bo ho.[2] Yare yi betumi anya mmoa afoforo, ebi ne nkraman ne nkura.[1]

Nsεm afoforo[sesa | edit source]

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Leishmaniasis Fact sheet N°375". World Health Organization. January 2014. Retrieved 17 February 2014. 
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Barrett, MP; Croft, SL (2012). "Management of trypanosomiasis and leishmaniasis.". British medical bulletin 104: 175–96. PMC 3530408. PMID 23137768. doi:10.1093/bmb/lds031. 
  3. 3.0 3.1 Sundar, S; Chakravarty, J (Jan 2013). "Leishmaniasis: an update of current pharmacotherapy.". Expert opinion on pharmacotherapy 14 (1): 53–63. PMID 23256501. doi:10.1517/14656566.2013.755515. 
  4. Dorlo, TP; Balasegaram, M; Beijnen, JH; de Vries, PJ (Nov 2012). "Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.". The Journal of antimicrobial chemotherapy 67 (11): 2576–97. PMID 22833634. doi:10.1093/jac/dks275. 
  5. Minodier, P; Parola, P (May 2007). "Cutaneous leishmaniasis treatment.". Travel medicine and infectious disease 5 (3): 150–8. PMID 17448941. doi:10.1016/j.tmaid.2006.09.004. 
  6. "Leishmaniasis Magnitude of the problem". World Health Organization. Retrieved 17 February 2014. 
  7. Lozano, R (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.". Lancet 380 (9859): 2095–128. PMID 23245604. doi:10.1016/S0140-6736(12)61728-0. 
  8. Ejazi, SA; Ali, N (Jan 2013). "Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.". Expert review of anti-infective therapy 11 (1): 79–98. PMID 23428104. doi:10.1586/eri.12.148.